Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 10.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,782,127 shares of the biotechnology company's stock after buying an additional 932,476 shares during the quarter. Vanguard Group Inc. owned about 8.78% of Coherus BioSciences worth $36,585,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Eagle Bay Advisors LLC lifted its position in shares of Coherus BioSciences by 136.1% during the second quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 2,243 shares in the last quarter. Captrust Financial Advisors boosted its stake in Coherus BioSciences by 1,461.0% in the 1st quarter. Captrust Financial Advisors now owns 2,404 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 2,250 shares during the period. Dorsey & Whitney Trust CO LLC purchased a new position in Coherus BioSciences during the 3rd quarter valued at about $39,000. Princeton Global Asset Management LLC bought a new stake in shares of Coherus BioSciences during the third quarter valued at about $39,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Coherus BioSciences by 55.0% in the third quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company's stock worth $41,000 after buying an additional 1,498 shares in the last quarter. 72.82% of the stock is owned by institutional investors.

Coherus BioSciences Trading Down 1.6 %

Shares of CHRS traded down $0.04 during midday trading on Thursday, reaching $2.41. The stock had a trading volume of 1,761,548 shares, compared to its average volume of 4,023,869. The company has a market capitalization of $271.63 million, a price-to-earnings ratio of -0.94 and a beta of 0.54. The company's 50-day moving average is $2.41 and its 200 day moving average is $2.61. Coherus BioSciences, Inc. has a 12-month low of $1.43 and a 12-month high of $8.65.

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) last issued its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.39). The business had revenue of $91.52 million during the quarter, compared to analyst estimates of $105.30 million. Research analysts forecast that Coherus BioSciences, Inc. will post -0.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on CHRS. HC Wainwright lowered their target price on shares of Coherus BioSciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday, March 20th. Truist Financial reduced their target price on Coherus BioSciences from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, January 23rd. Finally, Robert W. Baird decreased their target price on Coherus BioSciences from $11.00 to $9.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 23rd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Coherus BioSciences currently has a consensus rating of "Moderate Buy" and an average price target of $9.29.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.